1·The objective was to compare the efficacy of zolpidem tartrate and stilnox in the treatment for insomnia.
目的是比较酒石酸唑吡坦与噻诺克斯治疗失眠症的疗效。
2·At that time, the FDA requested additional data demonstrating that zolpidem does not present an unacceptable risk for next-day residual effects when used according to its proposed label.
在那个时候，FDA要求额外的数据证明按照它草拟的标签唑吡坦第二天残余效应不会导致无法接受的风险。
3·The results showed that after receiving zolpidem, the patient was able to stand up and walk, repeat words and sentences, read words, and name objects, although she was not able to speak spontaneously.
研究结果显示服用唑吡坦后，患者能站立并行走，重复词语和句子，读词语及命名物品，但她没有自发语言。